Want to see CLYM full AI Analyst Report?
Climb Bio (CLYM) Stock Statistics & Valuation Metrics
Total Valuation
Climb Bio has a market cap or net worth of $588.72M. The enterprise value is $811.24M.
- Market Cap
- $588.72M
- Enterprise Value
- $811.24M
Share Statistics
Climb Bio has 57,436,256 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 57,436,256
- Owned by Insiders
- 18.06%
- Owned by Institutions
- 35.10%
Financial Efficiency
Climb Bio’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -42.16%.
- Return on Equity (ROE)
- -0.37
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -42.16%
- Return on Capital Employed (ROCE)
- -0.42
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.14M
- Employee Count
- 28
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Climb Bio is -11.73. Climb Bio’s PEG ratio is 0.58.
- PE Ratio
- -11.73
- PS Ratio
- 0.00
- PB Ratio
- 3.10
- Price to FCF
- -10.54
- Price to Operating Cash Flow
- -14.08
- PEG Ratio
- 0.58
Income Statement
In the last 12 months, Climb Bio had revenue of 0 and earned -59.85M in profits. Earnings per share was -0.88.
- Revenue
- 0
- Gross Profit
- -97.00K
- Operating Income
- -67.88M
- Pretax Income
- -59.85M
- Net Income
- -59.85M
- EBITDA
- -59.75M
- Earnings Per Share (EPS)
- -0.88
Cash Flow
In the last 12 months, operating cash flow was -52.70M and capital expenditures -369,000, giving a free cash flow of -53.07M billion.
- Operating Cash Flow
- -52.70M
- Free Cash Flow
- -53.07M
- Free Cash Flow per Share
- -0.70
Dividends & Yields
Climb Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.36%
- Earnings Yield
- -7.67%
Stock Price Statistics
- Beta
- 1.70
- 52-Week Price Change
- 375.12%
- 50-Day Moving Average
- 12.57
- 200-Day Moving Average
- 10.50
- Relative Strength Index (RSI)
- 44.11
- Average Volume (3m)
- 1.41M
Important Dates
Climb Bio upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Climb Bio as a current ratio of 15.16, with Debt / Equity ratio of 0.34%
- Current Ratio
- 15.16
- Quick Ratio
- 15.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.59
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Climb Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Climb Bio EV to EBITDA ratio is -8.83, with an EV/FCF ratio of -9.88.
- EV to Sales
- 0.00
- EV to EBITDA
- -8.83
- EV to Free Cash Flow
- -9.88
- EV to Operating Cash Flow
- -9.94
Balance Sheet
Climb Bio has $183.12M in cash and marketable securities with $1.31M in debt, giving a net cash position of $181.81M billion.
- Cash & Marketable Securities
- $183.12M
- Total Debt
- $1.31M
- Net Cash
- $181.81M
- Net Cash Per Share
- $3.17
- Tangible Book Value Per Share
- $3.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Climb Bio is $28.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $28.60
- Price Target Upside
- 193.63% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -19.29%
Scores
- Smart Score
- 10
- AI Score
- 49
